Intensive care units' prevention of pneumonia in critically-ill patients generally strong

May 20, 2008

Mayo Clinic researchers found that the frequency with which critically-ill patients developed ventilator-associated pneumonia (VAP) is approximately the same at a multidisciplinary medical center such as Mayo Clinic compared to the average VAP-risk rate for 211 hospitals in the National Healthcare Safety Network (NHSN). This is good news for patients because it suggests that care levels are generally strong across the U.S. in intensive care units, which is where the sickest patients -- many of them elderly -- are treated. This is true despite variety in levels of care offered by individual hospitals.

The study also is helpful because it identified the fact that the VAP-risk rate for patients in a specific kind of intensive care unit, the trauma intensive care unit (TICU), was lower at Mayo Clinic, as compared to the NHSN average. This kind of finding is what the U.S. Centers for Disease Prevention and Control (CDC) intended when it made the NHSN data available in a June 2007 report. In that report, CDC analysts instructed hospitals to use the data to guide local prevention strategies and other quality improvement efforts aimed at reducing infection rates.

The Mayo group presented its findings this week at the American Thoracic Society’s 2008 International Conference in Toronto. The data showed that the Mayo Clinic risk rate for VAP in intensive care units (ICU) for trauma patients averaged 3.4 per 1,000 days of mechanical ventilation. This compares to the VAP average of 10.2 per 1,000 days in trauma ICUs participating in the NHSN.

The reason for this variation is not known, and the difference needs to be validated through further study. But these preliminary results identify a need for improvement to lower the 10.2 risk rate.

“The topic is an important one to study because developing VAP is a potential risk for all critically-ill patients who must be on an invasive mechanical ventilator greater than 48 hours,” says Mayo lead author Ahmed Mahmoud, M.B.B.S.

“As the demographics of this country change, the number of frail elderly who end up hospitalized and needing ventilation in a TICU is likely to increase,” adds senior author Bekele Afessa, M.D., of Mayo’s pulmonary and critical care medicine group. “We want to do our best to eliminate the potential for any additional disease burden to patients. Understanding the risk of VAP in all ICU settings is a step toward that.”

The Mayo study is the first to compare VAP-risk rates at (NHSN) hospitals to Mayo Clinic’s experience as a single advanced medical center with integrated intensive care units and a unified approach to infection control. Mayo Clinic researchers studied 206 patients treated at Mayo Clinic’s various ICUs between February and August 2007, and who consented to participate in the study.

The Mayo Clinic comparison also showed that:

-- The VAP-risk rate varies depending on the ICU medical specialty, from a low of 2.8 at Mayo Clinic’s vascular/thoracic surgery intensive care unit and 5.7 in the analogous units of NHSN to a high of 10.2 per 1,000 ventilator days in NHSN trauma intensive care units.

-- The Mayo VAP-risk data range from 2.8 to 8.2 across various kinds of ICUs at Mayo Clinic; 2.8 for vascular and thoracic surgery, 8.2 for neurology and 4.9 for cardiac surgery.

-- Of the 19 bacteria isolated from the patients, the Mayo study found that the most common pathogen causing VAP was Pseudomonas aeruginosa. This information is helpful in determining the best antibiotic treatment for VAP. Acting on it could perhaps help prevent levels of VAP elsewhere.

Source: Mayo Clinic


print this article email this article download pdf blog this article bookmark this article     Stumble it Digg this share on Facebook retweet share on Reddit add to delicious
Rate this story - not rated yet


May 20, 2008 all stories

Comments: 0

not rated yet
  • Stumble this up

  • Digg this

  • share this

  • hide
  • Related Stories




  • hide
  • Relevant PhysicsForums posts

  • Micro-voltmeter and microscopic instruments
    created Dec 22, 2009
  • Flush? [Thrush]
    created Dec 20, 2009
  • Undescended Testicles
    created Dec 20, 2009
  • strange lump o.O
    created Dec 18, 2009
  • More from Physics Forums - Medical Sciences

Other News

Genomic differences identified in common skin diseases

Medicine & Health / Research

created 8 hours ago | popularity 5 / 5 (1) | comments 0

(PhysOrg.com) -- If you have dry skin, wet it, if wet skin, dry it. This has been a general rule of dermatology for centuries, but scientists are working to develop more precise treatments for the dozen-plus inflammatory ...


Scientists discover how the brain encodes memories at a cellular level

Scientists discover how the brain encodes memories at a cellular level

Medicine & Health / Research

created 11 hours ago | popularity 5 / 5 (11) | comments 3

Scientists at UC Santa Barbara have made a major discovery in how the brain encodes memories. The finding, published in the December 24 issue of the journal Neuron, could eventually lead to the development ...


Genomic toggle switches divide autoimmune diseases into distinct clusters

Medicine & Health / Genetics

created 3 hours ago | popularity not rated yet | comments 0

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.


Scientists discover 2 genes that drive aggressive brain cancers

Medicine & Health / Cancer

created 9 hours ago | popularity 5 / 5 (1) | comments 0

A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancer.


Compound Halts Common Type of Drug-resistant Lung Cancer

Research yields new agent for some drug-resistant non-small cell lung cancers

Medicine & Health / Cancer

created 10 hours ago | popularity 5 / 5 (1) | comments 0

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant ...